Announcements Trials
Browse Landscape

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 2Neuromyelitis Optica 1Hemoglobinuria, Paroxysmal 1Atypical Hemolytic Uremic Syndrome 1

Interventions

Blood Specimen Collection 56Surveys and Questionnaires 53Specimen Handling 31Observation 18Radiotherapy 16Magnetic Resonance Spectroscopy 12Interviews as Topic 12Surgical Procedures, Operative 11Data Collection 11Biopsy 10Watchful Waiting 9Drug Therapy 9darolutamide 8Tomography, X-Ray Computed 8palbociclib 7Standard of Care 7Magnetic Resonance Imaging 7Immune Checkpoint Inhibitors 7ribociclib 6Patient Reported Outcome Measures 6Bevacizumab 6trastuzumab deruxtecan 5Ultrasonography 5Restraint, Physical 5Radiofrequency Ablation 5Mental Status and Dementia Tests 5Mastectomy, Segmental 5Mass Screening 5Genetic Testing 5Breath Tests 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × ravulizumab × 90 days × Clear all
NCT06909253 2026-05-15

MG-ARCADIA

AstraZeneca

Recruiting
50 enrolled

Myasthenia Gravis

NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔